PuraPharm Corporation Limited submitted its Monthly Return for Equity Issuer for the period ended 30 June 2026, confirming no changes in either authorised or issued share capital during the month.

Authorised Share Capital • Authorised share count remained at 5.00 trillion ordinary shares with a par value of USD 0.001, representing total authorised capital of USD 5.00 billion.

Issued Shares and Treasury Stock • Issued shares stood unchanged at 535.90 million. • The company held zero treasury shares, and there were no repurchases or cancellations.

Public Float Compliance • Management affirmed compliance with the Main Board’s minimum public-float requirement of 25%, ensuring adequate market liquidity.

Share Option Scheme Activity • Outstanding options under the 2015 Share Option Scheme totaled 23.96 million, with no options exercised, lapsed or cancelled in June. • A further 31.79 million shares remain available for future grants under the scheme.

Other Instruments • The company reported no outstanding warrants, convertible securities, or other agreements that could dilute the share base.

Overall, PuraPharm’s capital structure remained unchanged in June 2026, and regulatory float requirements continue to be met.